Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple heart pill boost lung cancer treatment?

NCT ID NCT05387512

Knowledge-focused Sponsor: Affiliated Hospital of Nantong University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked back at medical records of 60 people with advanced non-small cell lung cancer who received standard immunotherapy (anti-PD-1/PD-L1 drugs). Researchers checked whether those who also took beta-blockers (commonly used for heart conditions) had different outcomes, like how long the cancer stayed under control. The goal is to see if this common heart medication might influence how well immunotherapy works.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
beta-blocker (concomitant exposure during anti-PD-1/PD-L1 therapy)
What this could lead to
If beta-blockers are linked to better outcomes, this could point toward a simple, low-cost way to boost immunotherapy effectiveness in lung cancer.
What could go wrong
This is a small, retrospective observational study, not a controlled trial. It can only show an association, not cause and effect. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

60 people

The number who actually took part.

Started

Jun 2022

Finished

May 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This retrospective study included eligible patients with advanced non-small cell lung cancer who received standard anti-PD-1/PD-L1 inhibitor therapy in routine clinical practice at the Affiliated Hospital of Nantong University during the predefined study period. Clinical records and follow-up information were collected retrospectively. Patients were categorized into exposure cohorts according to documented concomitant long-term beta-blocker use during the anti-PD-1/PD-L1 treatment course.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years or older; * Histologically or cytologically confirmed advanced or metastatic non-small cell lung cancer; * Received standard anti-PD-1/PD-L1 inhibitor therapy during routine clinical care; * Available baseline clinical records and follow-up data sufficient for assessment of treatment exposure and clinical outcomes; Exclusion Criteria: * Incomplete baseline clinical records or follow-up data that preclude assessment of treatment exposure or clinical outcomes; * Concomitant participation in an interventional therapeutic clinical trial affecting the same treatment course, if applicable; * Other major clinical conditions or competing malignancies that preclude valid outcome assessment, according to the prespecified study protocol

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

lung cancer non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lung cancer Non-small cell lung cancer

Contacts and locations

Locations

  • Department of Pharmacy, Affiliated Hospital of Nantong University

    Nantong, Jiangsu, 226000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.